congenital cytomegalovirus

congenital cytomegalovirus
Name	Congenital cytomegalovirus
Field	Pediatrics; Infectious disease
Symptoms	Hearing loss, Microcephaly, Jaundice
Complications	Sensorineural hearing loss, Developmental delay
Onset	Neonatal period
Duration	Lifelong
Causes	Human cytomegalovirus
Risks	Pregnancy; Immunosuppression
Diagnosis	Polymerase chain reaction; Amniocentesis
Prevention	Hand washing; Vaccine
Treatment	Ganciclovir; Valganciclovir
Frequency	Approximately 0.2–2% of live births in many countries

congenital cytomegalovirus Congenital cytomegalovirus is a neonatal infectious condition resulting from in utero transmission of the Human cytomegalovirus and is a leading non-genetic cause of Sensorineural hearing loss and Neurodevelopmental delay. Infants may present with a spectrum from asymptomatic infection to severe multisystem disease including Microcephaly, Petechiae, and Hepatosplenomegaly. Recognition, targeted screening, and antiviral therapy are central to reducing long-term morbidity and are the focus of research programs at institutions such as Centers for Disease Control and Prevention, World Health Organization, and academic centers including Johns Hopkins University, Massachusetts General Hospital, and University of California, San Francisco.

Signs and symptoms

Clinical manifestations vary widely and can overlap with other congenital infections such as Rubella, Toxoplasmosis, and Zika virus infection. Symptomatic neonates commonly display Jaundice, Thrombocytopenia, Petechiae, Hepatosplenomegaly, Microcephaly, and respiratory distress prompting evaluation at centers like Great Ormond Street Hospital or Boston Children's Hospital. Sensorineural hearing loss may be present at birth or develop later, detected through programs modeled on screening initiatives by American Academy of Pediatrics, American Academy of Audiology, and national newborn screening efforts in United Kingdom and Australia. Neurologic signs include seizures, hypotonia, and imaging abnormalities similar to patterns reported by teams at Mayo Clinic, Stanford University School of Medicine, and Karolinska Institute.

Cause and pathophysiology

The etiologic agent is Human cytomegalovirus of the Herpesviridae family; transplacental transmission occurs primarily during maternal primary infection but can also arise from reactivation or reinfection with different strains. Viral invasion of the placenta and fetal tissues produces cytopathic effects, inflammatory responses, and vascular injury described in pathologic series from Johns Hopkins Hospital and Great Ormond Street Hospital. Viral tropism for neural progenitor cells, inner ear structures, and hepatic endothelium underlies the characteristic sequelae; mechanistic work has been advanced by laboratories at National Institutes of Health, Pasteur Institute, and University of Oxford. Host factors such as maternal immunity, timing of infection (first trimester versus later), and viral load determine severity, paralleling observations in cohorts from Norway, Japan, and Brazil.

Diagnosis

Diagnosis integrates laboratory virology, imaging, and clinical assessment as practiced in referral centers like Boston Children's Hospital and Sheba Medical Center. Definitive confirmation in the neonate relies on detection of viral DNA by Polymerase chain reaction from saliva, urine, or blood within the first three weeks of life; similar molecular approaches are standard at Mayo Clinic, Karolinska Institute, and public health laboratories within Centers for Disease Control and Prevention. Prenatal diagnosis may use maternal serology showing seroconversion, and fetal diagnosis via viral PCR on amniotic fluid obtained by Amniocentesis and interpreted in tertiary centers such as Cleveland Clinic and Royal Free Hospital. Neuroimaging with Magnetic resonance imaging or cranial Ultrasound identifies intracranial calcifications, ventriculomegaly, and cortical malformations and is guided by radiology protocols from American College of Radiology.

Prevention and screening

Prevention strategies emphasize maternal education, hygiene measures promoted by Centers for Disease Control and Prevention and World Health Organization, and vaccine development pursued by consortia including National Institutes of Health and private firms collaborating with Bill & Melinda Gates Foundation. Routine prenatal screening policies vary internationally; some programs in Israel, France, and parts of the United States target pregnant women for CMV serology, while universal newborn screening pilots have been implemented in jurisdictions inspired by advocates such as March of Dimes and researchers at University of Utah. Behavioral counseling focuses on reducing exposure to pediatric secretions in settings like Day care, with public health campaigns modeled on interventions used for Influenza and Rubella prevention.

Treatment and management

Antiviral therapy with intravenous Ganciclovir or oral Valganciclovir for symptomatic infants with CNS involvement reduces progression of hearing loss and improves neurodevelopmental outcomes in randomized trials coordinated by networks including European Society for Paediatric Infectious Diseases and International Congenital Cytomegalovirus Research Network. Management also requires multidisciplinary care—otolaryngology for hearing rehabilitation using protocols from American Speech-Language-Hearing Association, neurology for seizure control following guidelines of American Epilepsy Society, and developmental pediatrics with standards from American Academy of Pediatrics. Supportive care addresses thrombocytopenia, feeding difficulties, and liver dysfunction; teams at Seattle Children's Hospital and Children's Hospital of Philadelphia have published care pathways. Novel therapeutics and immunoprophylaxis remain under investigation in trials at National Institutes of Health and industry sponsors.

Epidemiology

Global prevalence of congenital infection is heterogeneous, with estimates from population studies by World Health Organization and national surveillance showing rates roughly 0.2–2% of live births, higher in parts of Sub-Saharan Africa, Southeast Asia, and Latin America. Seroprevalence among women of childbearing age varies by region and socioeconomic factors, documented in cohorts from United States Department of Health and Human Services, Public Health England, and research centers at Harvard Medical School and University of São Paulo. Incidence of symptomatic disease and long-term sequelae correlates with maternal primary infection rates and access to prenatal care, patterns analyzed in epidemiologic studies from Sweden, China, and South Africa.

Prognosis and long-term outcomes

Outcomes depend on symptom status at birth, timing of infection, and access to antiviral therapy and early intervention services provided by programs like Early Intervention (United States) and educational frameworks from UNICEF. Symptomatic neonates have higher risks of permanent sensorineural hearing loss, intellectual disability, and motor impairment, with longitudinal cohorts reported from Duke University Medical Center, University of Toronto, and Johns Hopkins University. Asymptomatic infants may still develop late-onset hearing loss, necessitating long-term audiologic surveillance in follow-up clinics modeled on those at Nationwide Children's Hospital and Royal Children's Hospital (Melbourne). Ongoing research aims to improve vaccine efficacy, antiviral tolerability, and public health screening policies guided by agencies such as European Centre for Disease Prevention and Control and Centers for Disease Control and Prevention.

Category:Congenital infections